1. Home
  2. AKRO vs ODD Comparison

AKRO vs ODD Comparison

Compare AKRO & ODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • ODD
  • Stock Information
  • Founded
  • AKRO 2017
  • ODD 2018
  • Country
  • AKRO United States
  • ODD Israel
  • Employees
  • AKRO N/A
  • ODD N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • ODD
  • Sector
  • AKRO Health Care
  • ODD
  • Exchange
  • AKRO Nasdaq
  • ODD Nasdaq
  • Market Cap
  • AKRO 3.9B
  • ODD 3.8B
  • IPO Year
  • AKRO 2019
  • ODD 2023
  • Fundamental
  • Price
  • AKRO $50.56
  • ODD $67.89
  • Analyst Decision
  • AKRO Strong Buy
  • ODD Buy
  • Analyst Count
  • AKRO 6
  • ODD 9
  • Target Price
  • AKRO $82.50
  • ODD $67.89
  • AVG Volume (30 Days)
  • AKRO 1.1M
  • ODD 923.1K
  • Earning Date
  • AKRO 08-08-2025
  • ODD 08-06-2025
  • Dividend Yield
  • AKRO N/A
  • ODD N/A
  • EPS Growth
  • AKRO N/A
  • ODD 45.36
  • EPS
  • AKRO N/A
  • ODD 1.74
  • Revenue
  • AKRO N/A
  • ODD $703,488,000.00
  • Revenue This Year
  • AKRO N/A
  • ODD $24.46
  • Revenue Next Year
  • AKRO N/A
  • ODD $20.26
  • P/E Ratio
  • AKRO N/A
  • ODD $39.09
  • Revenue Growth
  • AKRO N/A
  • ODD 26.83
  • 52 Week Low
  • AKRO $21.34
  • ODD $32.71
  • 52 Week High
  • AKRO $58.40
  • ODD $79.18
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 44.48
  • ODD 40.13
  • Support Level
  • AKRO $50.60
  • ODD $67.66
  • Resistance Level
  • AKRO $52.55
  • ODD $70.35
  • Average True Range (ATR)
  • AKRO 1.83
  • ODD 3.15
  • MACD
  • AKRO -0.35
  • ODD -0.74
  • Stochastic Oscillator
  • AKRO 17.66
  • ODD 2.82

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About ODD ODDITY Tech Ltd.

ODDITY Tech Ltd offers a consumer tech platform that is built to transform the beauty and wellness market. The ODDITY platform is designed to support a portfolio of brands and services that innovate and disrupt the expansive beauty and wellness market. It consumes user data to develop physical beauty and wellness products that deliver performance and functionality. Its brands include SpoiledChild and IL Makiage.

Share on Social Networks: